Patent: 12,077,791

Summary for Patent: 12,077,791

Title:	PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereof
Abstract:	Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
Inventor(s):	Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
Assignee:	Halozyme Inc , Halozyme Therapeutics Inc
Application Number:	US18/339,829
Patent Claims:	see list of patent claims

United States Patent 12,077,791: Claims, Claim-Scope Risk, and US Patent Landscape

What does US 12,077,791 claim, and where is the scope strongest?

US Patent 12,077,791 is not identifiable from the information available in this session. Without the patent’s full text claims, independent claim set, claim construction terms (as filed and/or in issued form), and key specification anchors, a complete, accurate claim-by-claim landscape analysis cannot be produced without fabricating details.

Result: No analysis is provided.

---

What is the competitive patent landscape around the same subject matter in the US?

A landscape assessment requires, at minimum, the target patent’s technology category and claim-defining limitations so prior art can be mapped to:

• anticipation risk under 35 USC 102,
• obviousness risk under 35 USC 103,
• design-around opportunities,
• continuations/divisionals affecting term and scope,
• and related families with overlapping claim coverage.

Because US 12,077,791’s claims and subject matter are not available here, a critical mapping to relevant US publications and granted patents would be incomplete or speculative.

Result: No analysis is provided.

---

Key Takeaways

• US 12,077,791 cannot be analyzed from the information present in this session.
• A “comprehensive and critical” claims and landscape review requires the patent’s actual claim language and specification-defined terms.
• Providing that review without the patent text would require assumptions that would invalidate the analysis.

---

FAQs

1. Can you summarize US 12,077,791’s independent claims without claim text?
   No.

2. Can you assess novelty and obviousness risk for US 12,077,791 without knowing its limitations?
   No.

3. Can you build a US prior-art landscape without identifying the technology class and claim terms?
   No.

4. Can you evaluate design-around strategies without the specific claim constraints?
   No.

5. Can you cite the relevant US publications and patents without querying them against the claim scope?
   No.

---

References

[1] No sources cited.

Details for Patent 12,077,791

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	October 25, 2005		2043-06-22

International Patent Family for US Patent 12,077,791

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2013102144
United States of America	9447401
United States of America	2025197836
United States of America	2025197835
United States of America	2025197834
United States of America	2025197833
United States of America	2025197832